Humana Adds Medicare Advantage Coverage for CVRx's Barostim Device
CVRX is trading near its 52-week low of $4.37 (22% below the low) on elevated volume (1.9× avg).
Summary
Humana has added Medicare Advantage coverage for CVRx's Barostim device, a significant reimbursement win that expands patient access and could accelerate U.S. revenue growth. This follows last night's Q2 report where revenue rose 16% to $15.7M but full-year guidance was cut to $58M–$60M. The Humana decision directly addresses the sales force disruption cited in the guidance cut by improving the reimbursement landscape. With shares trading near 52-week lows, this catalyst could shift sentiment if it translates into faster adoption.
At the time of this announcement, CVRX was trading at $3.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.6M. The 52-week trading range was $4.37 to $11.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.